BioDtech, Inc. (BDTI) offers new technologically superior products for the bioresearch and bioprocess markets, which are designed exclusively for the detection, neutralization and removal of endotoxin.

Current endotoxin assays accepted by the FDA and pharmacopeias worldwide are based on Limulus (horseshoe crab) amebocyte lysate (LAL) clotting in response to endotoxin. This assay lacks specificity and requires specific conditions for a delicate enzymatic reaction to occur. To circumvent these problems, the molecular site where endotoxin binds to Factor C enzyme to initiate the LAL clotting reaction (the sushi domain) has been identified and patented, and is made chemically rather than extracting from the horseshoe crab. This is the basis for BDTI's proprietary technology for the detection, neutralization and removal of endotoxin.

BioDtech's products address all of the concerns of the endotoxin market and will eliminate common critical issues associated with current methods. Using their reagents, the customer can design assays that are user friendly, yield rapid results that are quantitative and specific to endotoxin contamination without expensive training or equipment. Their products offer the scientist the ability to eliminate the effects of endotoxin contamination by neutralization and/or removal.